Keysight Technologies (NYSE: KEYS) launches wireless coexistence test platform for FDA-compliant devices

Keysight Technologies Inc. (NYSE: KEYS) has introduced a new Wireless Coexistence Test Solution aimed at helping engineers conduct automated, standards-aligned testing for wireless devices operating in interference-heavy RF environments. The launch signals a strategic move by Keysight to deepen its value proposition in regulated sectors like healthcare and industrial automation, where wireless reliability has become a gating factor for safety, compliance, and market access.

The test platform aligns with ANSI C63.27, a framework increasingly referenced by the U.S. Food and Drug Administration and other regulatory bodies for evaluating wireless performance in the presence of interference. By shifting compliance workflows from manual to automated, Keysight is targeting faster development cycles, better reproducibility, and earlier risk mitigation in product design. This is particularly relevant as connected medical devices and IoT systems proliferate in clinical and mission-critical environments where RF coexistence cannot be an afterthought.

Why is wireless coexistence testing becoming a strategic requirement in regulated device development?

Wireless devices are no longer limited to consumer-grade convenience. From glucose monitors and pacemakers to industrial sensors and smart surgical systems, wireless communication has become deeply embedded in safety-critical workflows. This shift has prompted regulators to increasingly treat RF performance as a compliance issue rather than an optional performance benchmark.

The U.S. Food and Drug Administration has recommended that device manufacturers follow ANSI C63.27 to assess wireless coexistence during design and premarket submissions. However, these tests are often time-consuming and require significant engineering bandwidth when done manually. In sectors where time-to-market is compressed and design iterations are frequent, delays in RF testing can cascade into missed regulatory windows and costly rework.

This is where Keysight’s platform stakes its relevance. By automating coexistence testing across all three tiers of ANSI C63.27 — from basic interference to complex multi-signal scenarios — the company positions itself as an enabler of both compliance and speed. Its built-in test libraries, vector signal generator, and simulation capabilities aim to close the gap between regulatory obligation and product innovation.

How does Keysight’s RF testing architecture help engineers reduce development cycle time?

The new platform is anchored on OpenTAP, Keysight’s open-source test sequencer that allows engineers to configure test plans, upload custom waveforms, and simulate real-world RF conditions in a virtualized environment. This modularity is key for companies developing multiple SKUs or operating in multi-band wireless ecosystems.

At the hardware layer, the solution integrates a wideband vector signal generator capable of operating from 9 kHz to 8.5 GHz — expandable to 110 GHz — with up to eight virtual signals and modulation bandwidths that can scale from 250 MHz to 2.5 GHz. This range enables developers to emulate dense RF conditions without the need for complex custom setups. Engineers can focus on analyzing device behavior rather than spending cycles managing hardware configurations.

The test suite also embeds nearly one hundred pre-configured scenarios, enabling repeatable test execution across use cases such as hospital telemetry systems, consumer wearables, and industrial control networks. The company claims the automation architecture reduces test cycle time by more than 50 percent, providing a measurable productivity gain that aligns with shrinking R&D timelines.

Why does this matter for Keysight’s competitive positioning in the test and measurement industry?

Keysight Technologies has long operated at the high end of the electronic test equipment market, but the company is increasingly moving into solution-centric workflows designed for sector-specific regulatory environments. By offering pre-compliance test automation targeted at healthcare, aerospace, automotive, and semiconductor clients, the company is creating deeper moats in segments that are less exposed to price competition and more sensitive to regulatory precision.

While rivals like Rohde & Schwarz, Anritsu, and National Instruments also offer wireless testing platforms, Keysight’s strength lies in its ability to integrate physical layer testing with simulation and standards-driven validation. This test-to-compliance architecture is particularly useful for original equipment manufacturers that must submit to agencies like the U.S. Food and Drug Administration, European Medicines Agency, or Japan’s Pharmaceuticals and Medical Devices Agency.

In that light, the coexistence solution is not just a product launch — it is part of a broader strategy to move beyond discrete instruments into software-defined, compliance-oriented engineering ecosystems. This platform-led approach aligns with the industry shift toward digital twin environments, continuous testing, and traceability across the product lifecycle.

How could this platform impact regulatory submissions, quality assurance, and R&D cost structures?

From a cost and compliance perspective, the automation of coexistence testing has several second-order effects. First, it minimizes the variance that arises from manual testing, which can be a source of regulatory friction when results are inconsistent across submissions. Second, it reduces the number of late-stage design iterations required when interference risks are identified too close to production. Third, it enables teams to shift validation left in the development cycle, integrating RF coexistence metrics alongside latency, throughput, and packet error rate analysis.

Keysight’s consulting layer — which offers custom KPI tracking and integration support — further embeds the platform into the quality management systems of device makers. That creates potential for subscription revenue models, longer sales cycles, and expanded enterprise-level relationships beyond individual R&D teams.

What are the capital allocation implications and next-phase execution risks for Keysight Technologies?

While Keysight Technologies has not disclosed new capital commitments tied to this platform, the release underscores a pivot toward solution bundling and deeper software integration — both of which could affect margin structure and sales team incentives over time. Investors may want to monitor whether the company reports increased backlog or pipeline conversion tied specifically to regulatory-driven platforms in future earnings cycles.

Execution risk remains tied to adoption. For the solution to scale beyond early adopters, Keysight will need to ensure that integration workflows, simulation capabilities, and cross-standard coverage remain robust across different regulatory jurisdictions and wireless protocols. Additionally, success will hinge on whether compliance teams and not just RF engineers view the platform as a must-have, thereby expanding its footprint within customer organizations.

What does this mean for public market sentiment around Keysight Technologies?

Shares of Keysight Technologies have been moderately volatile over the past 12 months, reflecting broader concerns about demand cycles in the electronics and communications testing segments. While the company has outperformed some peers in terms of margin resilience and product diversity, investor attention has increasingly shifted toward how well Keysight can transition from hardware to platform and services.

This launch may serve as a narrative bridge for that transition. If Keysight can demonstrate that it is monetizing regulatory complexity through automation, it could attract longer-duration capital from investors focused on compliance-as-a-service and mission-critical infrastructure themes. That said, near-term stock movement will likely remain tied to broader electronics end-market recovery and updates from large-cap clients in the semiconductor and communications verticals.

What does Keysight’s wireless coexistence platform signal for regulatory-driven test markets and competitive differentiation?

• Keysight Technologies has launched a new Wireless Coexistence Test Solution to automate ANSI C63.27-aligned testing for interference-heavy RF environments.

• The solution targets regulatory-heavy sectors like healthcare and medical devices, where wireless reliability is tied to patient safety and compliance.

• Automation of coexistence testing reduces manual errors, shortens development timelines, and improves submission-readiness for U.S. Food and Drug Administration and international agencies.

• The platform leverages OpenTAP, an open-source test sequencer, enabling simulation, customization, and scalable testing across a range of RF conditions.

• Integrated vector signal generation and built-in test scenarios enable end-to-end coverage without custom setups, improving engineering productivity.

• The platform aligns with Keysight’s broader strategy to move beyond instruments into regulatory-focused engineering solutions with software integration.

• Competitors like Rohde & Schwarz and Anritsu may face pressure to offer similar automation and regulatory alignment in their test platforms.

• Investor interest may hinge on Keysight’s ability to monetize regulatory complexity and demonstrate solution-led growth beyond hardware sales.

• Execution risk lies in scaling adoption across regulated sectors with diverse RF protocols and global compliance standards.

• The launch positions Keysight Technologies as a long-term infrastructure partner for clients building connected, compliant, and safety-critical devices.